CHILL BRANDS GROUP LS-01
Chill Brands Group PLC sells and distributes nicotine-free vape products and other consumer packaged-goods in the United States and United Kingdom. It offers nicotine-free vapes under the Chill ZERO brand. The company also provides nicotine pouches, vapes, beverages, supplements, and wellness products, as well as CBD oral chew pouches. It sells its products through a network of retail stores, e-c… Read more
CHILL BRANDS GROUP LS-01 (7HR) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CHILL BRANDS GROUP LS-01 (7HR) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CHILL BRANDS GROUP LS-01 - Net Assets Trend (None–None)
This chart illustrates how CHILL BRANDS GROUP LS-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CHILL BRANDS GROUP LS-01 (None–None)
The table below shows the annual net assets of CHILL BRANDS GROUP LS-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CHILL BRANDS GROUP LS-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CHILL BRANDS GROUP LS-01 Competitors by Market Cap
The table below lists competitors of CHILL BRANDS GROUP LS-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund
NYSE:PTA
|
$187.78K |
|
ATHENE HOLDING PRF.SER.C
F:ATR0
|
$187.87K |
|
Indivior PLC
LSE:INDV
|
$187.94K |
|
GETINGE -B-
BE:GTN
|
$188.03K |
|
Vision Sigma
TA:VISN
|
$187.55K |
|
FORTUM - Dusseldorf Stock Exchang
DU:FOT
|
$187.53K |
|
Sparindex INDEX Bæredygtige USA KL
CO:SPVBUSAKL
|
$187.50K |
|
CaNickel Mining Limited
PINK:CMLGF
|
$187.32K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CHILL BRANDS GROUP LS-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CHILL BRANDS GROUP LS-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CHILL BRANDS GROUP LS-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CHILL BRANDS GROUP LS-01's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CHILL BRANDS GROUP LS-01 (7HR) | €- | N/A | N/A | $187.55K |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $243.78K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.26K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $987.66 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $77.40 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $35.57 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.73 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |